Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate…
<!-- Name:DistributionId Value:8834229 -->
<!--…
Read More...
Read More...
Browsing Tag
ADMP
Adamis Announces Review of Strategic Alternatives
SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty…
Read More...
Read More...
Adamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamster Model
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that…
Read More...
Read More...
Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical…
Read More...
Read More...
Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update
SAN DIEGO, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical…
Read More...
Read More...
Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment…
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the…
Read More...
Read More...
Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19
SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that…
Read More...
Read More...
Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from NASDAQ
SAN DIEGO, May 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical…
Read More...
Read More...